Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-10-04
2009-12-08
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07629324
ABSTRACT:
The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and/or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.
REFERENCES:
patent: 6822087 (2004-11-01), Renzi
patent: 9622371 (1996-07-01), None
patent: 9632481 (1996-10-01), None
patent: 9636291 (1996-11-01), None
patent: 9720926 (1997-06-01), None
patent: 9722698 (1997-06-01), None
patent: 9702344 (1997-07-01), None
patent: 9728190 (1997-08-01), None
patent: 9741154 (1997-11-01), None
patent: 9741225 (1997-11-01), None
patent: 9913886 (1999-03-01), None
Allakhverdi et al. (American Journal of Respiratory and Critical Care Medicine, 2002 vol. 165:1015-1021).
Allakhverdi et al. (Annals of the New York Academy of Sciences, 2006 vol. 1082:62-73).
Fortin et al. (Oligonucleotides, 2006 vol. 16:203-212).
Jubinsky, Paul T. et al., Blood, 90(5):1867-1873 (1997). “The Beta-Chain of the Interleukin-3 Receptor Functionally Associates With the Erythropoietin Receptor.”
Devos R, et al., “Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease.” J Leukoc Biol 57(6):813-9, 1995.
Green DW, et al., “Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.” J Am Coll Surg 191(1):93-105, 2000.
Jen KY and Gewirtz AM, “Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.” Stem Cells 18(5):307-19, 2000.
Branch AD, “A good antisense molecule is hard to find.” Trends Biochem Sci 23(2):45-50, 1998.
Agrawal S and Kandimalla ER, “Antisense therapeutics: is it as simple as complementary base recognition?” Mol Med Today 6(2):72-81, 2000.
Ponath PD, et al., “Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.” J Exp Med 183(6):2437-48, 1996.
Ikizawa K, et al., “Inhibition of IL-4 receptor up-regulation on B cells by antisense oligodeoxynucleotide suppresses IL-4-induced human IgE production.” Clin Exp Immunol 100(3):383-9, 1995.
Hayashida K et al., “Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor.” Proc Natl Acad Sci U S A 87 (24):9655-9, 1990.
Gibbs Terra Cotta
McGarry Sean
Nixon & Peabody LLP
Topigen Pharmaceutiques Inc.
LandOfFree
Antisense oligonucleotides for treating atopic diseases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides for treating atopic diseases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides for treating atopic diseases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056168